Remo CRO

News

Relapsing-remitting MS: Alemtuzumab boosts outcomes for black patients

05.07 2017.

A trial reveals that the drug alemtuzumab may improve outcomes for black patients with relapsing-remitting multiple sclerosis, who are often understudied. Details

Don’t Let Your Job Title Keep You from Being a Clinical Research Leader

05.06 2017.

Have you reached a point in your clinical research career where you are itching for a change, but feel constrained by factors like not wanting to relocate, or seeing the next position you crave is already filled by someone who isn’t going to let it go anytime soon, or admitting that moving up the corporate […] Details

IBM uses Big Data to develop new strategies to help address Ebola

05.06 2017.

IBM has used big data analytics to assess the impact of infected animal carriers, or an animal reservoir, in the spread of the Ebola virus in a way not been previously done for earlier disease models. Direct contact with the infected animal—most likely a bat or large snake—whether by touching or eating it—can cause the […] Details

Disfiguring eye symptoms diminish in Graves' eye disease drug trial

05.06 2017.

The disease is characterized by inflammation and a buildup of tissue around the eyes that cause them to bulge painfully from their sockets. Details

eClinicalHealth, Chilli Consultancy launch COA development services

05.06 2017.

eClinicalHealth, a cloud-based remote clinical research technology company, and Chilli Consultancy, a statistical and patient-centered outcomes consulting firm, announce new streamlined clinical outcome assessment (COA) development services. iUsability, a new service to be jointly offered by eClinicalHealth and Chilli Consultancy is a novel patient usability testing service. The Integrated Usability Service or iUsability streamlines the […] Details

Avantor to acquire VWR for $6.4B

05.06 2017.

Avantor, a global supplier of ultra-high-purity materials for the life sciences and advanced technology industries, will acquire VWR, a major global independent provider of product, supply chain and service solutions to laboratory and production customers, for $33.25 in cash per share of VWR common stock, reflecting an enterprise value of approximately $6.4 billion. The purchase price represents an […] Details